drugset
drugset / Trial / NCT04180163

Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE)

NCT04180163 ↗

Phase 3 Completed 12 enrolled Shire
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this phase 3, open-label, multi-center study is to evaluate the safety and efficacy of lanadelumab in Japanese participants with HAE Type I or II.

Timeline

Start
2019-12-12
Primary completion
2021-08-26
Completion
2021-08-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Lanadelumab Monoclonal antibody 300 mg Subcutaneous

Indications

hereditary angioedema